Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2025-09-03 AGM Information
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
2025年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled '2025 年第三次临时股东大会会议资料' which translates to '2025 Third Extraordinary General Meeting (EGM) Materials'. It contains detailed meeting materials including meeting agenda, proposals for shareholder approval, voting instructions, and explanations of various proposals related to a specific capital raising event (private placement of A shares). The document includes multiple proposals for shareholder approval, detailed explanations of the issuance plan, pricing, use of proceeds, and authorization for the board to handle related matters. The content is clearly the meeting materials provided to shareholders for an extraordinary general meeting, not the announcement of voting results or a brief summary. It is not a full annual or interim report, nor a call transcript or earnings release. It is not a proxy solicitation or voting results announcement but the actual meeting materials. Therefore, the document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during a general meeting (including extraordinary meetings). The document length (over 12,000 characters) and detailed content confirm it is the meeting materials themselves, not just an announcement or notice.
2025-09-03 Chinese
关于2024年度“提质增效强回报”行动方案的半年度评估报告
Management Reports Classification · 90% confidence The document is titled as an "annual assessment report" for the company's 2024 "quality improvement and efficiency enhancement" action plan. It contains detailed operational and financial performance data for 2024 and the first half of 2025, including revenue, profit, business transformation, investor relations, governance, and compliance. The document is a comprehensive report on the progress and evaluation of a specific annual action plan rather than a full annual report (10-K) or interim report (IR). It is not a brief announcement or a certification but a substantive report with financial and operational details. The document length is 2763 characters, which is relatively short but contains detailed content. It does not fit into categories like earnings release, call transcript, or governance information specifically. The best fitting category is a Management Report (MDA) because it provides management's detailed explanation of business trends, financial results, and outlook related to the action plan.
2025-08-29 Chinese
关于公司2025年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising activities, specifically focusing on the storage and actual use of funds raised in 2025. It includes detailed financial figures about the amount raised, usage in previous years, current usage, and balances. It also references regulatory approvals and audit reports related to the fundraising. The document is titled as a "专项报告" (special report) on the half-year fundraising funds storage and usage situation for 2025. This type of document aligns with a Capital/Financing Update (CAP) as it provides updates on the company's fundraising and capital usage activities rather than a full annual or interim financial report. It is not an announcement of a report publication, nor a certification or proxy statement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-08-29 Chinese
关于召开2025年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 half-year performance explanation meeting (业绩说明会) for Tianyu Bio-Technology Co., Ltd. It mentions the date, time, location, participants, and how investors can participate and ask questions. It references the already published 2025 half-year report but does not contain the report itself or detailed financial data. The document is primarily an announcement of an investor presentation event rather than the presentation or report itself. Therefore, it fits best under the category of Investor Presentation (IP) as it is about a detailed presentation for investors focusing on financials and business performance.
2025-08-29 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "天域生物科技股份有限公司2025 年半年度报告" which translates to "Tianyu Bio-Technology Co., Ltd. 2025 Semi-Annual Report." It explicitly states it is a half-year report covering the period from January 1, 2025 to June 30, 2025. The content includes detailed financial data, management discussion and analysis, business overview, financial indicators, and other comprehensive information typical of an interim or quarterly report. The document length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-29 Chinese
第四届监事会第三十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Tianyu Biotech Co., Ltd. regarding the review and approval of the company's 2025 semi-annual report and a special report on the use of raised funds. It states that the Supervisory Board has reviewed and approved the 2025 semi-annual report and confirms its compliance with laws and regulations. However, the document itself does not contain the actual financial statements or detailed financial data of the semi-annual report; it only references that the full report is available on the Shanghai Stock Exchange website. The document is short (922 characters) and serves as an official announcement of the Supervisory Board's meeting resolutions rather than the report itself. Therefore, according to the "Menu vs Meal" rule, this document should be classified as a Regulatory Filing (RNS) because it is an official announcement related to regulatory compliance and disclosures but does not contain the full semi-annual report or substantive financial data.
2025-08-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.